Healthcare >> CEO Interviews >> January 27, 2003
DAVID C. DLESK joined Recovery Pharmaceuticals as CEO in 2001. He
has been associated with the company since 1999, first as an
adviser and investor, and later as a Director. Mr. Dlesk
previously served as Executive VP and Chief Business Officer of
V.I. Technologies where he established the commercialization
strategy for a new product to inactivate pathogens in blood. As
VP of Operations at Biogen he successfully managed the
operational launch and rapid growth of the blockbuster multiple
sclerosis drug, Avonex_ and guided a new $60 million biotech
production facility from groundbreaking through FDA licensure in
33 months. While CEO of Medical Media Systems, a start-up company
creating computer aided surgery systems, he oversaw the
development of a ground breaking 3-D surgical imaging device. Mr.
Dlesk began his career at Baxter Healthcare Corp. and held a
variety of positions including General Manager of Bentley
Laboratories B.V. and Director of Business Development, Venture
Technology. Mr. Dlesk holds BS and MS degrees in Industrial
Engineering from the University of Illinois, Urbana-Champaign. Profile
Pharmaceuticals and an overview of things as they are now?
Mr. Dlesk: We started the company four years ago as
